Literature DB >> 1969825

Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.

I Ahnfelt-Rønne1, O H Nielsen, A Christensen, E Langholz, V Binder, P Riis.   

Abstract

5-Aminosalicylic acid, the therapeutically active metabolite of sulfasalazine, was exposed to oxygen-derived free radicals produced by the Fenton reaction in vitro, and several metabolites were detected and characterized by high performance liquid chromatography and ultraviolet spectrophotometry. The majority of these metabolites were present in methanolic extracts of feces samples from sulfasalazine-treated patients with inflammatory bowel disease but not in rheumatoid arthritis patients with normal bowel function. The presence of these metabolites, which have not been demonstrated in vivo before, provides evidence of an interaction between 5-aminosalicylic acid and oxygen-derived free radicals in sulfasalazine-treated patients with inflammatory bowel disease. Since the concentration of lipid peroxides, which is dependent on the release of oxygen-derived free radicals, was significantly increased in pretreatment rectal biopsies of the patients, and further was normalized concomitantly with a significant improvement in disease activity over the 5-wk treatment period, an important role of the radical scavenger mechanism of 5-aminosalicylic acid in sulfasalazine therapy of chronic inflammatory bowel disease is strongly suggested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969825     DOI: 10.1016/0016-5085(90)90329-y

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

1.  5-Aminosalicylic acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro.

Authors:  J Kanski; C Lauderback; D A Butterfield
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

Review 2.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

3.  Comparative studies of superoxide production by microbial wall product-primed neutrophils in ulcerative colitis.

Authors:  Sara Elsøe Nielsen; Ben Vainer; Ole Haagen Nielsen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

4.  Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis.

Authors:  Shinichiro Tada; Hirotoshi Ebinuma; Hidetsugu Saito; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2006-04       Impact factor: 7.527

5.  Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats.

Authors:  C Loguercio; G D'Argenio; M Delle Cave; V Cosenza; N Della Valle; G Mazzacca; C del Vecchio Blanco
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

6.  Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis.

Authors:  Jeffrey B Brown; Goo Lee; Elizabeth Managlia; Gery R Grimm; Ramanarao Dirisina; Tatiana Goretsky; Paul Cheresh; Nichole R Blatner; Khashayarsha Khazaie; Guang-Yu Yang; Linheng Li; Terrence A Barrett
Journal:  Gastroenterology       Date:  2009-10-29       Impact factor: 22.682

7.  5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells.

Authors:  S M McKenzie; W F Doe; G D Buffinton
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

8.  Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease.

Authors:  B Sido; V Hack; A Hochlehnert; H Lipps; C Herfarth; W Dröge
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 9.  Role of neutrophil-derived oxidants in the pathogenesis of intestinal inflammation.

Authors:  T Yamada; M B Grisham
Journal:  Klin Wochenschr       Date:  1991-12-15

10.  A stable nitroxide radical effectively decreases mucosal damage in experimental colitis.

Authors:  F Karmeli; R Eliakim; E Okon; A Samuni; D Rachmilewitz
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.